CN108181214A - 使用atap肽治疗疾病的方法和组合物 - Google Patents
使用atap肽治疗疾病的方法和组合物 Download PDFInfo
- Publication number
- CN108181214A CN108181214A CN201810133004.5A CN201810133004A CN108181214A CN 108181214 A CN108181214 A CN 108181214A CN 201810133004 A CN201810133004 A CN 201810133004A CN 108181214 A CN108181214 A CN 108181214A
- Authority
- CN
- China
- Prior art keywords
- atap
- platinum
- irgd
- drug
- freeze
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 156
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 129
- 238000000034 method Methods 0.000 title claims abstract description 80
- 239000000203 mixture Substances 0.000 title claims abstract description 71
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 15
- 201000010099 disease Diseases 0.000 title claims abstract description 14
- 238000011282 treatment Methods 0.000 title abstract description 19
- HIIJOGIBQXHFKE-HHKYUTTNSA-N Ala-Thr-Ala-Pro Chemical group C[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O HIIJOGIBQXHFKE-HHKYUTTNSA-N 0.000 title abstract 5
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims abstract description 301
- 239000003814 drug Substances 0.000 claims abstract description 238
- 229910052697 platinum Inorganic materials 0.000 claims abstract description 164
- 229920001184 polypeptide Polymers 0.000 claims abstract description 116
- 229940079593 drug Drugs 0.000 claims abstract description 97
- 238000002360 preparation method Methods 0.000 claims abstract description 83
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 64
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 64
- 238000002648 combination therapy Methods 0.000 claims abstract description 5
- 238000012372 quality testing Methods 0.000 claims abstract description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 162
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 122
- 239000000243 solution Substances 0.000 claims description 80
- 239000011780 sodium chloride Substances 0.000 claims description 61
- 238000004108 freeze drying Methods 0.000 claims description 58
- 238000002347 injection Methods 0.000 claims description 57
- 239000007924 injection Substances 0.000 claims description 57
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 45
- 229960004562 carboplatin Drugs 0.000 claims description 37
- 190000008236 carboplatin Chemical compound 0.000 claims description 36
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 32
- 239000007788 liquid Substances 0.000 claims description 26
- 229960001756 oxaliplatin Drugs 0.000 claims description 26
- 201000011510 cancer Diseases 0.000 claims description 25
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 25
- 239000002552 dosage form Substances 0.000 claims description 23
- 150000003057 platinum Chemical class 0.000 claims description 23
- XSMVECZRZBFTIZ-UHFFFAOYSA-M [2-(aminomethyl)cyclobutyl]methanamine;2-oxidopropanoate;platinum(4+) Chemical compound [Pt+4].CC([O-])C([O-])=O.NCC1CCC1CN XSMVECZRZBFTIZ-UHFFFAOYSA-M 0.000 claims description 22
- 229950008991 lobaplatin Drugs 0.000 claims description 22
- -1 Song Bo Chemical compound 0.000 claims description 19
- 239000007787 solid Substances 0.000 claims description 15
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 14
- 229930195725 Mannitol Natural products 0.000 claims description 14
- 238000001914 filtration Methods 0.000 claims description 14
- 239000000594 mannitol Substances 0.000 claims description 14
- 235000010355 mannitol Nutrition 0.000 claims description 14
- 239000002245 particle Substances 0.000 claims description 14
- 239000008215 water for injection Substances 0.000 claims description 14
- 239000000654 additive Substances 0.000 claims description 13
- 230000001954 sterilising effect Effects 0.000 claims description 13
- 238000004659 sterilization and disinfection Methods 0.000 claims description 13
- 229950007221 nedaplatin Drugs 0.000 claims description 12
- 238000004090 dissolution Methods 0.000 claims description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 10
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 9
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 9
- 190000032366 Miboplatin Chemical compound 0.000 claims description 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 9
- 229930006000 Sucrose Natural products 0.000 claims description 9
- 239000000460 chlorine Substances 0.000 claims description 9
- 229910052801 chlorine Inorganic materials 0.000 claims description 9
- 239000008101 lactose Substances 0.000 claims description 9
- 201000005202 lung cancer Diseases 0.000 claims description 9
- 208000020816 lung neoplasm Diseases 0.000 claims description 9
- 229950002777 miboplatin Drugs 0.000 claims description 9
- 239000013618 particulate matter Substances 0.000 claims description 9
- FHMDYDAXYDRBGZ-UHFFFAOYSA-N platinum tin Chemical compound [Sn].[Pt] FHMDYDAXYDRBGZ-UHFFFAOYSA-N 0.000 claims description 9
- 229960005399 satraplatin Drugs 0.000 claims description 9
- 190014017285 satraplatin Chemical compound 0.000 claims description 9
- 235000015170 shellfish Nutrition 0.000 claims description 9
- 239000005720 sucrose Substances 0.000 claims description 9
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 8
- 230000000996 additive effect Effects 0.000 claims description 8
- 239000008103 glucose Substances 0.000 claims description 8
- 239000008174 sterile solution Substances 0.000 claims description 8
- 208000032839 leukemia Diseases 0.000 claims description 7
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 6
- 206010017758 gastric cancer Diseases 0.000 claims description 6
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 6
- 238000007689 inspection Methods 0.000 claims description 6
- 201000001441 melanoma Diseases 0.000 claims description 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 6
- 201000011549 stomach cancer Diseases 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 4
- 208000017604 Hodgkin disease Diseases 0.000 claims description 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 4
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 4
- 208000009956 adenocarcinoma Diseases 0.000 claims description 4
- 201000001531 bladder carcinoma Diseases 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 208000012804 lymphangiosarcoma Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 4
- 208000010570 urinary bladder carcinoma Diseases 0.000 claims description 4
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 230000003760 hair shine Effects 0.000 claims description 3
- 201000008968 osteosarcoma Diseases 0.000 claims description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 206010046766 uterine cancer Diseases 0.000 claims description 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims description 2
- 201000003076 Angiosarcoma Diseases 0.000 claims description 2
- 206010003571 Astrocytoma Diseases 0.000 claims description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 2
- 208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 208000005243 Chondrosarcoma Diseases 0.000 claims description 2
- 201000009047 Chordoma Diseases 0.000 claims description 2
- 208000006332 Choriocarcinoma Diseases 0.000 claims description 2
- 208000009798 Craniopharyngioma Diseases 0.000 claims description 2
- 201000009051 Embryonal Carcinoma Diseases 0.000 claims description 2
- 206010014967 Ependymoma Diseases 0.000 claims description 2
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 claims description 2
- 208000036566 Erythroleukaemia Diseases 0.000 claims description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 2
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims description 2
- 208000018142 Leiomyosarcoma Diseases 0.000 claims description 2
- 206010024305 Leukaemia monocytic Diseases 0.000 claims description 2
- 208000000172 Medulloblastoma Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 208000007641 Pinealoma Diseases 0.000 claims description 2
- 201000010208 Seminoma Diseases 0.000 claims description 2
- 208000014070 Vestibular schwannoma Diseases 0.000 claims description 2
- 208000008383 Wilms tumor Diseases 0.000 claims description 2
- 208000004064 acoustic neuroma Diseases 0.000 claims description 2
- 208000017733 acquired polycythemia vera Diseases 0.000 claims description 2
- 208000021841 acute erythroid leukemia Diseases 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000009060 clear cell adenocarcinoma Diseases 0.000 claims description 2
- 208000002445 cystadenocarcinoma Diseases 0.000 claims description 2
- 208000010932 epithelial neoplasm Diseases 0.000 claims description 2
- 210000004907 gland Anatomy 0.000 claims description 2
- 201000002222 hemangioblastoma Diseases 0.000 claims description 2
- 201000002313 intestinal cancer Diseases 0.000 claims description 2
- 201000006894 monocytic leukemia Diseases 0.000 claims description 2
- 208000001611 myxosarcoma Diseases 0.000 claims description 2
- 210000002569 neuron Anatomy 0.000 claims description 2
- 210000002445 nipple Anatomy 0.000 claims description 2
- 201000010198 papillary carcinoma Diseases 0.000 claims description 2
- 208000024724 pineal body neoplasm Diseases 0.000 claims description 2
- 201000004123 pineal gland cancer Diseases 0.000 claims description 2
- 208000037244 polycythemia vera Diseases 0.000 claims description 2
- 230000002207 retinal effect Effects 0.000 claims description 2
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 claims description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
- 190000005734 Nedaplatin Chemical compound 0.000 claims 3
- 206010000830 Acute leukaemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000001258 Hemangiosarcoma Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 201000000564 macroglobulinemia Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 28
- 230000000259 anti-tumor effect Effects 0.000 abstract description 6
- YHTTWXCDIRTOQX-FQJIPJFPSA-N (6S,9S,15S,18R,23R,26S,29S)-18-amino-6-(4-aminobutyl)-9,26-bis(carboxymethyl)-15-[3-(diaminomethylideneamino)propyl]-2,5,8,11,14,17,25,28-octaoxo-20,21-dithia-1,4,7,10,13,16,24,27-octazabicyclo[27.3.0]dotriacontane-23-carboxylic acid Chemical compound NCCCC[C@@H]1NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]2CCCN2C(=O)CNC1=O)C(O)=O YHTTWXCDIRTOQX-FQJIPJFPSA-N 0.000 abstract description 4
- 229960005540 iRGD Drugs 0.000 abstract description 4
- 229940090044 injection Drugs 0.000 description 48
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 20
- 239000000843 powder Substances 0.000 description 19
- 239000000047 product Substances 0.000 description 17
- 230000002776 aggregation Effects 0.000 description 16
- 238000004220 aggregation Methods 0.000 description 16
- 239000003607 modifier Substances 0.000 description 16
- 230000002401 inhibitory effect Effects 0.000 description 15
- 239000000890 drug combination Substances 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- 230000006907 apoptotic process Effects 0.000 description 9
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 9
- 230000004071 biological effect Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 6
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 239000001509 sodium citrate Substances 0.000 description 6
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 210000003470 mitochondria Anatomy 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 241000699660 Mus musculus Species 0.000 description 4
- 230000002424 anti-apoptotic effect Effects 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 4
- 239000003005 anticarcinogenic agent Substances 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000011580 nude mouse model Methods 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N oxalic acid group Chemical group C(C(=O)O)(=O)O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 230000002438 mitochondrial effect Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- 102000051485 Bcl-2 family Human genes 0.000 description 2
- 108700038897 Bcl-2 family Proteins 0.000 description 2
- 208000019838 Blood disease Diseases 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000004873 anchoring Methods 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 230000004611 cancer cell death Effects 0.000 description 2
- 208000019065 cervical carcinoma Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 208000014951 hematologic disease Diseases 0.000 description 2
- 208000018706 hematopoietic system disease Diseases 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 239000003182 parenteral nutrition solution Substances 0.000 description 2
- HRGDZIGMBDGFTC-UHFFFAOYSA-N platinum(2+) Chemical compound [Pt+2] HRGDZIGMBDGFTC-UHFFFAOYSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 101100011368 Caenorhabditis elegans egl-1 gene Proteins 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102100028735 Dachshund homolog 1 Human genes 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- 230000010337 G2 phase Effects 0.000 description 1
- 101000915055 Homo sapiens Dachshund homolog 1 Proteins 0.000 description 1
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 description 1
- 101000955934 Homo sapiens Vacuolar protein sorting-associated protein 53 homolog Proteins 0.000 description 1
- 235000002710 Ilex cornuta Nutrition 0.000 description 1
- 241001310146 Ilex cornuta Species 0.000 description 1
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 235000010326 Osmanthus heterophyllus Nutrition 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 description 1
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 102100029860 Suppressor of tumorigenicity 20 protein Human genes 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000010523 cascade reaction Methods 0.000 description 1
- 101150039936 ced-9 gene Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- CCQPAEQGAVNNIA-UHFFFAOYSA-N cyclobutane-1,1-dicarboxylic acid Chemical class OC(=O)C1(C(O)=O)CCC1 CCQPAEQGAVNNIA-UHFFFAOYSA-N 0.000 description 1
- SSJXIUAHEKJCMH-UHFFFAOYSA-N cyclohexane-1,2-diamine Chemical compound NC1CCCCC1N SSJXIUAHEKJCMH-UHFFFAOYSA-N 0.000 description 1
- LRCTTYSATZVTRI-UHFFFAOYSA-L cyclohexane-1,2-diamine;platinum(4+);tetradecanoate Chemical compound [Pt+4].NC1CCCCC1N.CCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCC([O-])=O LRCTTYSATZVTRI-UHFFFAOYSA-L 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229940093181 glucose injection Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000012155 injection solvent Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000008155 medical solution Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 229950004962 miriplatin Drugs 0.000 description 1
- 230000033607 mismatch repair Effects 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 208000017708 myomatous neoplasm Diseases 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 230000009701 normal cell proliferation Effects 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000006919 peptide aggregation Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 210000005267 prostate cell Anatomy 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000004336 spermatogonium Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1761—Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/02—Investigating particle size or size distribution
- G01N15/0205—Investigating particle size or size distribution by optical means
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N2015/1024—Counting particles by non-optical means
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Dispersion Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
组别 | 瘤重(g) | 抑瘤率% |
G1 | 0.955±0.125 | — |
G2 | 0.604±0.102* | 36.75 |
G3 | 0.516±0.104* | 45.96 |
G4 | 0.559±0.126* | 41.46 |
G5 | 0.495±0.094** | 48.16 |
G6 | 0.385±0.136* | 59.68 |
G7 | 0.315±0.081** | 67.01 |
G8 | 0.224±0.094** | 76.54 |
G9 | 0.155±0.126** | 83.77 |
组别 | 瘤重(g) | 抑瘤率% |
G1 | 0.897±0.103 | — |
G2 | 0.613±0.109* | 31.66 |
G3 | 0.578±0.132* | 35.56 |
G4 | 0.571±0.095** | 36.34 |
G5 | 0.512±0.121* | 42.92 |
G6 | 0.209±0.087** | 76.70 |
G7 | 0.274±0.116* | 69.45 |
G8 | 0.170±0.098** | 81.04 |
G9 | 0.086±0.092** | 90.41 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810133004.5A CN108181214B (zh) | 2018-02-09 | 2018-02-09 | 使用atap肽治疗疾病的方法和组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810133004.5A CN108181214B (zh) | 2018-02-09 | 2018-02-09 | 使用atap肽治疗疾病的方法和组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108181214A true CN108181214A (zh) | 2018-06-19 |
CN108181214B CN108181214B (zh) | 2020-06-30 |
Family
ID=62552532
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810133004.5A Active CN108181214B (zh) | 2018-02-09 | 2018-02-09 | 使用atap肽治疗疾病的方法和组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108181214B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN118184759A (zh) * | 2024-03-25 | 2024-06-14 | 北京爱泰浦生物医药科技有限责任公司 | Atap多肽及其疫苗的制备方法和应用 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101557818A (zh) * | 2006-10-03 | 2009-10-14 | 新泽西医科和牙科大学 | Atap肽、编码atap肽的核酸以及相关的应用方法 |
CN101679499A (zh) * | 2007-04-11 | 2010-03-24 | 基因信号国际公司 | 抗肿瘤药物、药剂、组合物及其用途 |
CN101921313A (zh) * | 2010-04-07 | 2010-12-22 | 武汉凯泰新生物技术有限公司 | 治疗或预防癌症的多肽或其衍生产品及应用 |
CN101948541A (zh) * | 2005-06-20 | 2011-01-19 | 健泰科生物技术公司 | 用于肿瘤诊断和治疗的组合物和方法 |
CN102177174A (zh) * | 2008-05-14 | 2011-09-07 | 分子基术事业化集团(株) | 用于靶向凋亡细胞的肽及其用途 |
CN102671218A (zh) * | 2012-06-11 | 2012-09-19 | 毛一雷 | 一种用于制备99mTc-GSA的冻干粉药盒及其制备方法和应用 |
CN104017083A (zh) * | 2005-04-15 | 2014-09-03 | 亚利桑那癌症治疗公司 | 用于治疗转移性癌症的治疗肽 |
CN106232621A (zh) * | 2014-02-14 | 2016-12-14 | 基因信号国际公司 | 用于治疗癌症的168a‑t2的多肽片段及包含其的组合物 |
CN106255679A (zh) * | 2014-02-27 | 2016-12-21 | 默克专利有限公司 | 用作na v通道抑制剂的杂环化合物及其用途 |
CN106999491A (zh) * | 2014-11-28 | 2017-08-01 | 兴和株式会社 | 医药 |
-
2018
- 2018-02-09 CN CN201810133004.5A patent/CN108181214B/zh active Active
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104017083A (zh) * | 2005-04-15 | 2014-09-03 | 亚利桑那癌症治疗公司 | 用于治疗转移性癌症的治疗肽 |
CN101948541A (zh) * | 2005-06-20 | 2011-01-19 | 健泰科生物技术公司 | 用于肿瘤诊断和治疗的组合物和方法 |
CN101557818A (zh) * | 2006-10-03 | 2009-10-14 | 新泽西医科和牙科大学 | Atap肽、编码atap肽的核酸以及相关的应用方法 |
CN101679499A (zh) * | 2007-04-11 | 2010-03-24 | 基因信号国际公司 | 抗肿瘤药物、药剂、组合物及其用途 |
CN102177174A (zh) * | 2008-05-14 | 2011-09-07 | 分子基术事业化集团(株) | 用于靶向凋亡细胞的肽及其用途 |
CN101921313A (zh) * | 2010-04-07 | 2010-12-22 | 武汉凯泰新生物技术有限公司 | 治疗或预防癌症的多肽或其衍生产品及应用 |
CN102671218A (zh) * | 2012-06-11 | 2012-09-19 | 毛一雷 | 一种用于制备99mTc-GSA的冻干粉药盒及其制备方法和应用 |
CN106232621A (zh) * | 2014-02-14 | 2016-12-14 | 基因信号国际公司 | 用于治疗癌症的168a‑t2的多肽片段及包含其的组合物 |
CN106255679A (zh) * | 2014-02-27 | 2016-12-21 | 默克专利有限公司 | 用作na v通道抑制剂的杂环化合物及其用途 |
CN106999491A (zh) * | 2014-11-28 | 2017-08-01 | 兴和株式会社 | 医药 |
Non-Patent Citations (2)
Title |
---|
GEJING DE ET AL.: "Amphipathic tail-anchoring peptide is a promising therapeutic agent for prostate cancer treatment", 《ONCOTARGET》 * |
国家药典委员会编: "《《中华人民共和国药典》2015年版四部》", 31 July 2015 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN118184759A (zh) * | 2024-03-25 | 2024-06-14 | 北京爱泰浦生物医药科技有限责任公司 | Atap多肽及其疫苗的制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN108181214B (zh) | 2020-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101352490B1 (ko) | 신규 리포좀 조성물 | |
JP6050822B2 (ja) | ナノ粒子、ナノ粒子の調製のための処理、および癌治療および食品関連化合物を含む医療分野における両親媒性分子または疎水性分子ための担体としてのナノ粒子の使用 | |
JP5579057B2 (ja) | 再発性癌の処置のための方法および組成物 | |
CA2909349C (en) | Use of a multi-agent composition for treatment of cancer | |
EP1332755A1 (en) | Taxol liposome composition for treatment of cancer and preparation thereof | |
KR20190009842A (ko) | 항암제로서 라파마이신 및 알부민을 포함하는 나노입자 | |
Chi et al. | Antitumor evaluation of carboxymethyl chitosan based norcantharidin conjugates against gastric cancer as novel polymer therapeutics | |
CN110279864A (zh) | 治疗肺癌的方法 | |
Zhang et al. | Rational design of anticancer platinum (IV) prodrugs | |
CN109730998A (zh) | 米铂白蛋白纳米粒组合物及其制法 | |
Saeed et al. | Synthesis and characterization of lipophilic salts of metformin to improve its repurposing for cancer therapy | |
JP2018517759A (ja) | カルボプラチンを含む組成物及び用途 | |
KR101395858B1 (ko) | 다당류 리포솜, 이의 제조 방법 및 용도 | |
US11634465B2 (en) | Analogues of VDAC1-derived peptides | |
CN108181214A (zh) | 使用atap肽治疗疾病的方法和组合物 | |
Xu et al. | Arene–Arene Coupled Disulfamethazines (or Sulfadiazine)-Phenanthroline-Metal (II) Complexes were Synthesized by In Situ Reactions and Inhibited the Growth and Development of Triple-Negative Breast Cancer through the Synergistic Effect of Antiangiogenesis, Anti-Inflammation, Pro-Apoptosis, and Cuproptosis | |
EA007481B1 (ru) | Цисплатиновые составы пониженной токсичности и способы их применения | |
CN108014325B (zh) | 多肽在治疗癌症中的应用 | |
CN114126660A (zh) | 药物复合物及其制备方法和用途 | |
US20240261375A1 (en) | Pharmaceutical composition for treating or preventing disorder associated with administration of anticancer agent | |
CN108324692A (zh) | Atap多肽和紫杉醇类药物共晶药及其制备方法和应用 | |
CN112823808B (zh) | 用于制备治疗上皮细胞癌的医药组合物及其用途 | |
RU2784869C1 (ru) | Чиаураниб для лечения мелкоклеточного рака легкого | |
US20160296574A1 (en) | Ephedra alata extracts and methods of use thereof | |
CN112294829A (zh) | 红景天苷在制备治疗或预防癌症的药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Liu He Inventor after: Guo Xiaochun Inventor after: Yang Huiren Inventor after: Ma Jianjie Inventor after: Guo Erming Inventor after: Wang Xinghui Inventor before: Liu He Inventor before: Shi Weiguo Inventor before: Guo Xiaochun Inventor before: Yang Huiren Inventor before: Ma Jianjie Inventor before: Guo Erming Inventor before: Wang Xinghui |